HSP90AA1 and neoplasm: Finally, in patient 4, a mutation in TOP2B identified in all tumour regions could indicate that the patient would benefit from treatment with a topoisomerase inhibitor and another mutation in HSP90AA1 (also identified in all tumour regions) could possibly lead to a better response to anthracyclines and cisplatin.